In this episode of The Tech Talks Daily Podcast, we explore the intersection of AI and cloud technology in the biotech industry with Stephen Deasy, CTO of Benchling.

Benchling is empowering scientists across the globe with a unified platform that supports faster, more efficient research and development, aiming to unlock the full potential of biotechnology.

Stephen discusses how AI is transforming drug discovery through specialized models like AlphaFold and BioNemo, while also warning that without updates to development, testing, and manufacturing, we may face challenges in keeping pace with AI-driven breakthroughs. He emphasizes that modern science needs modern technology to fully capitalize on these innovations.

We also examine how cloud technology is revolutionizing R&D in biotech, allowing companies to innovate rapidly, scale effectively, and focus on core research without getting bogged down in infrastructure management. Stephen shares how Benchling has helped organizations like Sanofi streamline their operations by consolidating legacy systems and creating high-quality, accessible data structures that maximize the impact of AI.

Stephen also highlights ongoing challenges, such as data quality and accessibility, and offers insights into how organizations can successfully integrate AI into their research. He provides valuable advice on fostering cross-functional collaboration, improving onboarding, and ensuring data readiness as key steps to maximizing the potential of AI in biotech.

How can the biotech industry ensure that the speed and scale of AI-driven drug discovery translate into real-world success? Join the discussion, and let us know your thoughts.